Related Experiment Videos
Radioimmunotherapy of B-cell NHL
1University of Alabama at Birmingham, Comprehensive Cancer Center, Department of Radiation Oncology, Birmingham, AL 35233, USA. Rmeredith@uabmc.edu
Current Pharmaceutical Biotechnology
|January 5, 2002
Summary
Radioimmunotherapy (RIT) shows promising response rates and durable remissions for non-Hodgkin
Area of Science:
- Oncology
- Immunotherapy
- Radiopharmaceutical Therapy
Background:
- Non-Hodgkin's Lymphoma (NHL) treatment has advanced with radionuclide-carrying antibody therapy (radioimmunotherapy or RIT).
- RIT has demonstrated significant efficacy in patients with relapsed NHL after primary therapies.
Purpose of the Study:
- To evaluate the progress and clinical impact of RIT in treating NHL.
- To compare the efficacy and toxicity of RIT with unlabeled antibody therapy and chemotherapy.
Main Methods:
- Review of clinical trials and patient data on RIT for NHL.
- Comparison of response rates, duration of response, and toxicity profiles between RIT, unlabeled antibody therapy, and chemotherapy.
Main Results:
- RIT achieved response rates exceeding 60% (nonmyeloablative) and 85%-100% (myeloablative).
- Response durations with RIT were often longer than with prior chemotherapy.
- RIT demonstrated higher response rates than unlabeled antibody therapy, with a favorable toxicity profile compared to chemotherapy.
Conclusions:
- RIT is an effective and increasingly utilized therapeutic modality for NHL.
- While RIT offers advantages, further research is needed to optimize its role in NHL treatment.
- RIT presents a favorable toxicity profile, with transient marrow suppression and a small risk of secondary malignancy as key considerations.